Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other May 16 | 2022Movano and Embecta Q1 ’22 Earnings Updates; Hygieia Launches d-Nav Clinical Partnership Program in MichiganPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other May 13 | 2022Tirzepatide Approved in US as "Mounjaro"Purchase Blast
$599
Posted in: Insulin Delivery, Other May 12 | 2022Zealand and Dario Q1 ’22 Earnings Updates; NexImmune, Yale, and JDRF research collaboration for T1DMPurchase Blast
$599
Posted in: Glucagon, Other May 11 | 2022Novo Highlights CV Risks of Diabetes in Unbranded Campaign Featuring Anthony Anderson; Xeris Q1 ’22 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring, Other May 10 | 2022Senseonics, Viatris, and Bayer Q1 ’22 Earnings Updates; Novo and Flagship Pioneering Collaboration; First Patient Dosed in Adocia Ph3 BC Lispro TrialPurchase Blast
$599
Posted in: Bolus Insulin, Insulin Delivery, Other May 06 | 2022Insulet, Vertex, MannKind, and Intercept Q1 ‘22 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, SGLT2i May 05 | 2022Novo Q1 '22 London Earnings; Lilly Initiates Second Trial in Ph3 QWINT Program; Ionis, Provention Bio, Lexicon, and Lannett Q1 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Insulin Delivery, Other May 05 | 2022Tandem, Amarin, and Regeneron Q1 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: SGLT2i May 05 | 2022DELIVER Delivers for AZ; Priority Review Depends on CV DeathPurchase Blast
$599
Posted in: Glucose Monitoring, Other May 03 | 2022Lilly and Genesis Therapeutics Collaboration; Esperion Q1 ’22 Earnings Update; Oramed’s Pivotal Ph3 Oral Insulin Trial Completes Enrollment; MySugarWatch Launches HCP-focused Ad Campaign for sugarBEAT in MIMSPurchase Blast
$599
Posted in: Insulin Delivery, Other May 02 | 2022Beta Bionics Insulin-only iLet Pivotal Trial Results @ ATTD 2022; Vertex's Ph1/2 VX-880 Trial Placed on Clinical HoldPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Apr 29 | 2022Novo, Dexcom, AZ, Sanofi, Biocon, and Teladoc Q1 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin Apr 28 | 2022Novo Reports First QW Basal Insulin Icodec Ph3 DataPurchase Blast
$599
Posted in: Dual/triple agonist, SGLT2i Apr 28 | 2022Did Lilly Cure Obesity? SURMOUNT-1 Topline Results; Q1 ‘22 Earnings UpdatesPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Apr 28 | 2022ATTD 2022 Key Press Releases (April 27); Abbott, Ypsomed, and CamDiab to develop AID SystemPurchase Blast
$599
Posted in: Glucose Monitoring Apr 20 | 2022Abbott Q1 ’22 Earnings Update; New YouTube Video Featuring Libre 2 AppPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other, SGLT2i Apr 19 | 2022Daprodustat NDA Accepted by FDA; Sean Saint Looks to Do It Again; April 19-22 CHMP Agenda; J&J Q1 ’22 Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other, SGLT2i Apr 14 | 2022New Medtronic 780G + Lyumjev Trial; Xigduo XR DAPA-CKD sNDA approved; Galectin NASH Trial to Continue; Sciwind Initiates Ph1 Oral GLP-1RA TrialPurchase Blast
$599
Posted in: Basal Insulin, Other Apr 13 | 2022Viatris Glargine Recalled; Carbon Health Launches Diabetes Management ProgramPurchase Blast